CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 35 enrolled
Drug / intervention
Tamoxifendrug
Likely dose
Tamoxifen 20 mg orally dailyAI-extracted
Key inclusion· 6
  • ✓Locally advanced breast cancer, Stage IIB or III
  • ✓Pathologically confirmed ER-positive or PR-positive breast cancer
  • ✓ER or PR Allred Score >4
  • ✓Age ≥18 years
Key exclusion· 3
  • ✕Prior chemotherapy, radiation therapy, or biologic therapy for invasive breast cancer within the past 5 years
  • ✕Pregnant or nursing
  • ✕Prior malignancy except adequately treated skin cancer, in situ cervical cancer, or disease-free for 5+ years

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02806544
NCT02806544Phase 2Completed
CompareCT.gov

Neoadjuvant Endocrine Therapy in Locally Advanced Hormone Receptor Positive Breast Cancer in a Low-Resource, Middle-Income Setting (Guatemala)

Vanderbilt University·interventional·Posted Jun 20, 2016·Updated Jan 30, 2017

In Brief

A Phase 2 clinical trial evaluating Tamoxifen for Breast Cancer and Breast Neoplasms. Completed, enrolled 35 participants.

Detailed Summary

This study evaluates the feasibility and efficacy of neoadjuvant tamoxifen for patients with locally advanced hormone receptor positive breast cancer in a low/middle income country.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer, Breast Neoplasms
Countries--
CollaboratorsWashington University School of Medicine, Instituto National de Cancerologia, Guatemala

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJun 20, 2016
Enrollment StartJan 1, 2013
Primary CompletionSep 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 10.0 years ago

Interventions

Tamoxifendrug

Tamoxifen 20mg by mouth daily